icrf 198 has been researched along with 1,2-bis(3,5-dioxopiperazin-1-yl)ethane in 1 studies
Studies (icrf 198) | Trials (icrf 198) | Recent Studies (post-2010) (icrf 198) | Studies (1,2-bis(3,5-dioxopiperazin-1-yl)ethane) | Trials (1,2-bis(3,5-dioxopiperazin-1-yl)ethane) | Recent Studies (post-2010) (1,2-bis(3,5-dioxopiperazin-1-yl)ethane) |
---|---|---|---|---|---|
24 | 0 | 4 | 22 | 0 | 2 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chadwick, DP; Clark, JR; Ferrans, VJ; Hasinoff, BB; Herman, EH; Zhang, J | 1 |
1 other study(ies) available for icrf 198 and 1,2-bis(3,5-dioxopiperazin-1-yl)ethane
Article | Year |
---|---|
Comparison of the protective effects against chronic doxorubicin cardiotoxicity and the rates of iron (III) displacement reactions of ICRF-187 and other bisdiketopiperazines.
Topics: Animals; Antibiotics, Antineoplastic; Cardiovascular Agents; Chelating Agents; Diketopiperazines; DNA Topoisomerases, Type II; Doxorubicin; Ethylenediamines; Glycine; Heart; Hydrolysis; Iron; Male; Myocardium; Piperazines; Rats; Rats, Inbred SHR; Razoxane | 1997 |